ES2187529T3 - Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal. - Google Patents

Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal.

Info

Publication number
ES2187529T3
ES2187529T3 ES94923816T ES94923816T ES2187529T3 ES 2187529 T3 ES2187529 T3 ES 2187529T3 ES 94923816 T ES94923816 T ES 94923816T ES 94923816 T ES94923816 T ES 94923816T ES 2187529 T3 ES2187529 T3 ES 2187529T3
Authority
ES
Spain
Prior art keywords
pct
chain
sequence
human
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94923816T
Other languages
English (en)
Inventor
Walter Fred Imperial Ca Bodmer
Helga Imperial Cancer R Durbin
David Imperial Cancer Re Snary
Lorna Mary Dyet Imp Ca Stewart
Susan Imperial Cancer Re Young
Paul Alan Imperial Cance Bates
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Original Assignee
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Technology Ltd filed Critical Cancer Research Technology Ltd
Application granted granted Critical
Publication of ES2187529T3 publication Critical patent/ES2187529T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UNA MOLECULA QUE (I) SE FIJA A UN ANTIGENO CARCINOEMBRIONICO DE UNION DE MEMBRANA HUMANA, (II) AGLOMERA UN POLIPEPTIDO HIBRIDO QUE CONSTA DE RESIDUOS 1 A 314 DE GLICOPROTEINA BILIARIA HUMANA UNIDA (N-C) A RESIDUOS 490 A C-TERMINUS DE ANTIGENO CARCINOEMBRIONICO HUMANO, PERO (III) NO SE FIJA A LA GLICOPROTEINA BILIARIA HUMANA EXCLUYENDO UN ANTICUERPO MONOCLONAL DE RATA INTACTO QUE CONSTA DE UN GRUPO IGG DE CADENA PESADA IIA Y UN GRUPO KAPPA DE CADENA LIGERA V DONDE LA SECUENCIA DE **FORMULA** O, DONDE LA SECUENCIA DE LA CADENA **FORMULA** ES COMO MOSTRADA ANTERIORMENTE, PERO EL PRIMER RESIDUO AMINOACIDO DE LA CDR1 ES UN GLUTAMINA Y EN CUALQUIER CASO LA SECUENCIA DE LA CADENA ES **FORMULA** .PREFERIBLEMENTE LA MOLECULA ES UN ANTICUERPO MONOCLONAL.
ES94923816T 1993-08-21 1994-08-19 Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal. Expired - Lifetime ES2187529T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939317423A GB9317423D0 (en) 1993-08-21 1993-08-21 Monoclonal antibodies

Publications (1)

Publication Number Publication Date
ES2187529T3 true ES2187529T3 (es) 2003-06-16

Family

ID=10740834

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94923816T Expired - Lifetime ES2187529T3 (es) 1993-08-21 1994-08-19 Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal.

Country Status (12)

Country Link
US (1) US5965710A (es)
EP (1) EP0721470B1 (es)
JP (1) JP3492373B2 (es)
AT (1) ATE226596T1 (es)
AU (1) AU7390694A (es)
CA (1) CA2168440C (es)
DE (1) DE69431602T2 (es)
DK (1) DK0721470T3 (es)
ES (1) ES2187529T3 (es)
GB (1) GB9317423D0 (es)
PT (1) PT721470E (es)
WO (1) WO1995006067A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5872215A (en) * 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9621295D0 (en) * 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
US6417337B1 (en) * 1996-10-31 2002-07-09 The Dow Chemical Company High affinity humanized anti-CEA monoclonal antibodies
WO1999006834A2 (en) * 1997-08-04 1999-02-11 Ixsys, Incorporated Methods for identifying ligand specific binding molecules
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
AU6940700A (en) * 1999-08-26 2001-03-19 Amy P. N Skubitz Peptides capable of modulating the function of cd66 (ceacam) family members
US6835549B2 (en) * 2000-02-24 2004-12-28 University Of Medicine & Dentistry Of New Jersey Immunoassay method for the diagnosis of gastric intestinal metaplasia associated with gastric carcinoma
US6774209B1 (en) 2000-04-03 2004-08-10 Dyax Corp. Binding peptides for carcinoembryonic antigen (CEA)
EP1472276A4 (en) * 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
CA2439402A1 (en) * 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
PT2000545E (pt) * 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
US20040229215A1 (en) * 2003-03-04 2004-11-18 Auburn University Methods of forming monolayers of phage-derived products and uses thereof
WO2005114444A1 (en) * 2004-04-30 2005-12-01 America Online, Inc. Network configuration management
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
AU2005286876A1 (en) * 2004-09-20 2006-03-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multiple mode multiplex reaction quenching method
KR101527334B1 (ko) 2005-08-11 2015-06-09 알피 마토씨안-로저스 자가면역 질병의 치료 및 진단용 ｔｃｒ-ｖ-베타 관련 펩티드
EP1940355B1 (en) 2005-09-30 2012-12-19 Auburn University Targeted drug delivery nanocarrier comprising a targeting landscape phage protein assembly
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
AU2008351621B2 (en) * 2008-02-29 2013-05-09 Signalomics Gmbh Optimized adhesin fragments and corresponding nanoparticles
KR101528013B1 (ko) * 2009-08-31 2015-06-16 로슈 글리카트 아게 친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
CA2773515C (en) * 2009-09-29 2015-04-28 Roche Glycart Ag Bispecific death receptor agonistic antibodies
WO2011109769A1 (en) 2010-03-04 2011-09-09 Ventana Medical Systems, Inc. Processing system for processing specimens using acoustic energy
US10539487B2 (en) 2010-03-04 2020-01-21 Ventana Medical Systems, Inc. Systems and methods for monitoring tissue sample processing
US10126216B2 (en) 2011-02-17 2018-11-13 Ventana Medical Systems, Inc. Method for tissue sample fixation
PE20141017A1 (es) * 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
CA2882757A1 (en) * 2012-08-31 2014-03-06 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
KR20250024741A (ko) 2022-03-23 2025-02-19 시나픽스 비.브이. 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU625613B2 (en) * 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies

Also Published As

Publication number Publication date
WO1995006067A1 (en) 1995-03-02
DK0721470T3 (da) 2003-02-24
DE69431602T2 (de) 2003-06-26
DE69431602D1 (de) 2002-11-28
AU7390694A (en) 1995-03-21
EP0721470B1 (en) 2002-10-23
JPH09501571A (ja) 1997-02-18
PT721470E (pt) 2003-03-31
ATE226596T1 (de) 2002-11-15
EP0721470A1 (en) 1996-07-17
CA2168440A1 (en) 1995-03-02
JP3492373B2 (ja) 2004-02-03
GB9317423D0 (en) 1993-10-06
US5965710A (en) 1999-10-12
CA2168440C (en) 2002-07-23

Similar Documents

Publication Publication Date Title
ES2187529T3 (es) Anticuerpos monoclonales utilizados para el diagnostico y el tratamiento del cancer colorrectal.
Ehrlich et al. Mixing two monoclonal antibodies yields enhanced affinity for antigen.
RU2006107453A (ru) Полипептидные композиции, связывающие cd20
PE20240819A1 (es) Anticuerpos anti-hla-g y uso de estos
PT699237E (pt) Fvs de cadeia anti-egfr e anticorpos anti-egfr
KR970700513A (ko) 백혈구 부착 분자 vla-4에 대한 인체화된 항체(humanized antibodies against leukocyte adhesion molecule vla-4)
GEP20063752B (en) Humanized Anti-LT-Beta-R Antibodies
HRP20020693B1 (hr) HUMANIZIRANA PROTUTIJELA KOJA SADRŽE PEPTID Aß
CA2451680A1 (en) Human dr4 antibodies and uses thereof
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
CO4850562A1 (es) Proceso para producir una preparacion concentrada de anticuerpos
ATE427966T1 (de) Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind
ATE350478T1 (de) Monoklonaler antikoerper gegen cea, konjugate die dieses antikoerper enthalten und deren therapeutische verwendung in einem adept-system
HRP20030805B1 (hr) Rekombinantna protutijela povezana s gangliozidima i njihova upotreba u dijagnostici i liječenju tumora
Terness et al. The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope.
JP2023506017A5 (es)
KR940006602A (ko) 면역글로불린 이소타입에 대한 재조형 모노클로날 항체
Giardina et al. The generation of monoclonal anti-idiotype antibodies to human B cell-derived leukemias and lymphomas.
RU95109930A (ru) Композиция, моноклональное антитело, полипептид, способ лечения
IL319999A (en) Bispecific antibodies against CD3 and CD20 - for the treatment of Richter syndrome
Mach Recombinant monoclonal antibodies, from tumor targeting to cancer immunotherapy: a critical overview
GB2611211A (en) Anti-CTLA4 monoclonal antibodies and chimeric antigen receptors
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
Guillien et al. Specificity of antibodies in single cells after immunization with antigens bearing several antigenic determinants: Study with a new paired staining technique
Nakao et al. A monoclonal antibody (H227) recognizing a new epitope of 4F2 molecular complex associated with T cell activation